Quercetin Inhibits Migration and Invasion of SAS Human Oral Cancer Cells through Inhibition of NF-KB and Matrix Metalloproteinase-2/-9 Signaling Pathways

WAN-WEN LAI¹, SHU-CHUN HSU³, FU-SHIH CHUEH⁷, YA-YIN CHEN⁴, JAI-SING YANG⁴, JING-PIN LIN², JIN-CHERNG LIEN⁶, CHUNG-HUNG TSAI^{1,8*} and JING-GUNG CHUNG^{5*}

¹Institute of Medicine, School of Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C.; Schools of ²Chinese Medicine, Departments of ³Nutrition, ⁴Pharmacology, and ⁵Biological Science and Technology,

⁶Graduate Institute of Pharmaceutical Chemistry, China Medical University, Taichung, Taiwan, R.O.C.;

⁷Departments of Health and Nutrition Biotechnology, Asia University, Taichung, Taiwan, R.O.C.;

⁸Department of Pathology, Chung Shan Medical University Hospital, Taichung, Taiwan, R.O.C.

Abstract. Quercetin, a principal flavanoid compound in onions, has been shown to possess a wide spectrum of pharmacological properties, including anticancer activities. Our earlier study showed that quercetin induced cytotoxic effects on SAS human oral cancer cells. In this study, we found that quercetin significantly reduced wound closure of SAS cells in culture plates after 12- and 24-h treatments. Results indicated that quercetin inhibited the expression and activity of matrix metalloproteinase (MMP)-2 and MMP-9, as measured by western blotting and gelatin zymography. The results from western blotting also showed that quercetin reduced the protein levels of MMP-2, -7, -9 and -10, vascular endothelial growth factor (VEGF), nuclear factor kappa-light-chainenhancer of activated B cells (NF-KB) p65, inductible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), urokinasetype plasminogen activator (uPA), phosphatidylinositide-3 kinases (PI3K), nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (IKB α), IKB- α/β , phosphorylated nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor kinase, alpha/ beta (p-IKK α/β),

*These Authors contributed equally to this study.

Correspondence to: Jing-Gung Chung, Department of Biological Science and Technology, China Medical University, No. 91, Hsueh-Shih Road, Taichung 404, Taiwan, R.O.C. Tel: +886 422053366 ext. 2161, Fax: +886 422053764, e-mail: jgchung@mail.cmu.edu.tw and Chung-Hung Tsai, Department of Pathology, Chung Shan Medical University Hospital, No. 110, Sec. 1, Chein-Kuo N. Road, Taichung 402, Taiwan, R.O.C. Tel: +886 424739595 ext. 11623, Fax: +886 424753984, e-mail: patholog@csmu.edu.tw

Key Words: Quercetin, migration, invasion, MMP-2, MMP-9, NF-KB, SAS human oral cancer cells.

focal adhesion kinase (FAK), son of sevenless homolog-1 (SOS1), growth factor receptor-bound protein-2 (GRB2), mitogen-activated protein kinase kinase kinase-3 (MEKK3), MEKK7, extracellular-signal-regulated kinase 1/2 (ERK1/2), p-ERK1/2, c-Jun N-terminal kinase 1/2 (JNK1/2), p38, p-p38, Jun proto-oncogene (c-JUN) and p-c-JUN but it did not affect Ras homolog gene family, member A (RhoA), Protein kinase C (PKC) and rat sarcoma viral oncogene homolog (RAS) in SAS cells. Confocal laser microscopy also showed that quercetin promoted the expressions of RhoA and Rhoassociated, coiled-coil containing protein kinase-1 (ROCK1), but inhibited the expression of NF-KB p65 in SAS cells. It is concluded from these data that inhibition of migration and invasion of SAS cells by quercetin is associated with the downregulation of PKC and RhoA by blocking MAPK and PI3K/AKT signaling pathways and NF-KB and uPA, resulting in inhibition of MMP-2 and MMP-9 signaling.

In Taiwan, approximately 10 individuals per 100,000 die annually from oral cancer, which it is the fourth most common type of cancer and the sixth cause of death in the entire population, based on the 2010 report from the Department of Health, R.O.C. (Taiwan) (1). Factors related to oral cancer include cigarette smoking, chewing of betel quid, and alcohol consumption (2). Betel quid chewing is one of the major factors in Taiwan (3). Current treatments (surgery, radiotherapy and chemotherapy) for oral cancer are still unsatisfactory (4); furthermore, oral cancer also metastasizes and causes cancer in other organs or tissues of patients (5).

Metastasis involves cytoskeletal proteins, and changed cell adhesion ability may influence cell motility, including invasion and migration of tumors cells (6, 7). It is well-documented that when cells metastasize, matrix metalloproteinases (MMPs) and the urokinase plasminogen activator (uPA), associated with cell invasion and migration, are overexpressed (8, 9). Therefore, it was suggested that use of an agent to inhibit MMP expression or MMP enzyme activity (9-11) and uPA (12-14) may prevent cancer metastasis.

Quercetin (3,3',4',5,7-pentahydroxyflavone), a bioactive plant flavonoid, has been shown to induce cytotoxic effects such as anti-proliferation, induction of apoptosis and cellcycle arrest in many human cancer cell lines (15-19). Numerous lines of evidence have also shown that guercetin induces cytotoxic effects on human cancer cells via cellular signal transduction pathways including change of the ratio of pro-apoptotic Bcl-2-associated X protein (BAX) and antiapoptotic B-cell lymphoma-2 (BCL2) proteins, and mitogenactivated protein kinases (MAPKs) and protein kinase B (AKT) levels (19, 20). It was reported that quercetin is a potential inhibitor of phosphatidylinositide-3 kinases (PI3K), an enzyme involved in the pivotal cell survival pathway (21, 22). Although many studies have shown the cytotoxic effects and the possible mechanisms of quercetin action, whether and how quercetin inhibits the migration and invasion of oral cancer cells is still unclear. In the current study, we investigated the molecular signaling pathways of quercetininduced inhibition of migration and invasion in human oral cancer SAS cells.

Materials and Methods

Materials and reagents. Quercetin, dimethyl sulfoxide (DMSO), propidium iodide (PI), ribonuclease-A, trypan blue, and Tris-HCl were obtained from Sigma-Aldrich Corp. (St. Louis, MO, USA). Dulbecco's modified Eagle's medium (DMEM), L-glutamine, fetal bovine serum (FBS), penicillin-streptomycin, and trypsin-EDTA were obtained from Life Technologies (Carlsbad, CA, USA). Primary antibodies for MMP-9 (cat. AB19016) and FAK (cat. 05-537) were purchased from Merck Millipore (Billerica, MA, USA), and antibodies against MMP-2, MMP-7, growth factor receptorbound protein 2 (GRB2), cyclooxygenase-2 (COX-2), extracellularsignal-regulated kinase 1/2 (ERK1/2), Ras homolog gene family, member A (RhoA), phosphatidylinositide 3-kinases (PI3K), phosphorylated extracellular signal-regulated kinase (p-ERK), protein kinase C (PKC), rat sarcoma viral oncogene homolog (RAS), son of sevenless homolog-1 (SOS1), inductible nitric oxide synthase (iNOS) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-KB) and secondary antibodies, were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA) and diluted in PBS Tween-20 before use.

SAS cell culture and treatment. The SAS cell line (human oral squamous cell carcinoma) was kindly provided by Dr. Pei-Jung Lu (Graduate Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan). Cells were immediately plated onto 75 cm² tissue culture flasks with DMEM with 2 mM L-glutamine adjusted to contain 10% FBS, 100 Units/ml penicillin and 100 µg/ml streptomycin. Then cells were maintained in 5% CO₂ at 37°C until reaching approximately 50-70% confluence for further treatment. Cells at a density of 2×10⁵ cells/well were maintained in a 12-well plate for 24 h then were treated with 25, 50, 100, 150, 200 and



Figure 1. Quercetin affected the percentage of viable SAS cells in vitro. Cells were placed in RPMI-1640 medium + 10% Fetal bovine serum (FBS) with 25, 50, 100, 150, 200 and 400 μ M of quercetin for 24 h. The cells were collected and were analyzed for viability by flow cytometry, as described in Materials and Methods. Each point is the mean±S.D. of three experiments.

400 μ M of quercetin for 24 h. Cells were then harvested and were stained with PI (4 μ g/ml) then analyzed by flow cytometry (FACS calibur flow cytometer; BD Biosciences, San Jose, CA, USA) as previously described (23, 24).

Wound-closure migration assay. Cells were allowed to form a confluent monolayer in 6-well plates at 5×10^5 cells/well and then cells were wounded with a 200-µl pipette tip, as described previously (12, 25). After being washed twice with PBS, all cells in the dish were treated with or without quercetin at a final concentration of 0, 25 or 50 µM and then were incubated in fresh DMEM with 1% FBS for 24 h. Photographs were taken using a phase-contrast microscope. The wound closure was monitored for 24 h. The cell-free area of each treatment in the dish was observed and measured by an inverted microscope (OlympusIX71, Tokyo, Japan) as described previously (23). Cell migration was calculated as the percentage of the remaining cell-free area compared with the area of the initial wound. Each test was performed triplicates.

In vitro migration assay of SAS cells. Cell migration was assessed using chemotactic directional migration by using a 24-well Transwell insert (25, 26). About 30 µg type-I collagen (Merck Millipore) was used to coat the 8 µm pore filters (Cat. PIEP12R48; Merck Millipore) for 1 h then cells at a density of 10⁴ cells/0.4 ml in DMEM were placed in the upper chamber and treated with 0.5% DMSO (as a control) or with quercetin (25 and 50 µM) then allowed to migrate for 24/48 h. A cotton swab was used to remove non-migrated cells in the upper chamber and the filter from each treatment was individually stained with 2% crystal violet. Migrated cells adherent to the underside of the filter were stained and photographed and then were counted under a light microscope at ×200. Each treatment including a control was assayed twice and three independent experiments were conducted as previously (25, 26).



Figure 2. Quercetin inhibited the migration of SAS cells. Cells were exposed to different concentrations (0, 25 and 50 μ M) of quercetin for 0, 12 and 24 h then the migration distance of cells was evaluated by a wound-healing assay at 0, 12, and 24 h time points, as described in Materials and Methods.

In vitro invasion assay of SAS cells. Cell invasion assay was performed by using Matrigel-coated transwell cell culture chambers (8 µm pore size) (12, 27). Cells were cultured for 24 h in serum-free-DMEM then were collected and re-suspended in serum-free medium. The membrane at the bottom of the Transwell chamber was coated with 50 µl Matrigel (BD Biosciences, San Jose, CA, USA) and airdried in a laminar hood overnight. Cells at a density of 5×10^4 cells/well were placed in the upper chamber of the transwell insert and treated with 0.5% DMSO (as a control) or quercetin (25 and 50 µM). Medium containing 10% FBS was placed in the lower chamber and cells were then incubated at 37°C in 5% CO2 atmosphere for 24 or 48 h. Non-penetrated cells were removed (which were maintained) in the upper chamber by using a cotton swab and the invasive cells in the lower surface of the filter which penetrated through the Matrigel were fixed with 4% formaldehyde in PBS and stained with 2% crystal violet in 2% ethanol. Cells were then counted and photographed under a light microscope at ×200 as described previously (12, 27).

Gelatin zymography for determination of MMP-2/-9 activity. The activity of MMP-2 and -9 in SAS cells was determined by gelatin zymography. In brief, cells (2×10^6 cells/well) were plated in 6-well tissue culture plates and were incubated in serum-free DMEM in the presence of 10, 15, 20, 25 and 50 μ M quercetin for 24 h. The conditioned medium from each sample was collected by centrifugation then was separated by electrophoresis on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) containing 0.1% gelatin. After electrophoresis, the gel were soaked in

2.5% Triton X-100 in dH₂O twice for a total of 60 min at 25°C, then were incubated for 18 h in substrate buffer (50 mM Tris HCl, 5 mM CaCl₂, 0.02% NaN₃ and 1% Triton X-100, pH 8.0) at 37°C (19). Bands corresponding to activity of MMP-2 and -9 were visualized by negative staining using 0.3% Coomassie blue in 50% methanol and 10% acetic acid as described previously (12, 26).

Western blotting analysis. SAS cells (1×106 cells/well) were placed in 6-well plates and then incubated with quercetin (25 and 50 µM) for 24 and 48 h at 80% culture confluence were harvested and resuspended in PRO-PREP TM protein extraction solution (iNtRON Biotechnology, Seongnam-si, Gyeonggi-do, Korea). The homogenate from each sample was centrifuged at 13,000 ×g for 10 min at 4°C to remove cell debris and collect the supernatant. Bio-Rad protein assay kit (Hercules, CA, USA) was used to measure the total protein from each sample of supernatant. Proteins from each sample (40 µg) were separated by 10% SDS-PAGE and were transferred to an Immobilon-P transfer membrane (cat. IPVH00010; Merck Millipore) as described previously (25, 28, 29). Primary antibodies were used and then the membrane was washed for secondary antibody staining. The bound antibodies from each sample were visualized using Immobilon Western Chemiluminescent HRP Substrate (cat. WBKLS0500; Merck Millipore) and X-ray film (GE Healthcare, Piscataway, NJ, USA).

Confocal laser scanning microscopy showed protein translocation in SAS cells. Cells (5×10^4 cells/well) were placed on 4-well chamber slides, and quercetin at a final concentration of 25 μ M was added to cells for 24 h. At the end of incubation, cells on the slides were fixed



Figure 3. Quercetin-affected cell migration and invasion of SAS cells. Cells were treated with 0, 25 and 50 μ M of quercetin for 24 and 48 h. Cell migration was examined in a Boyden chamber and transwell with polycarbonate filters (A); Cell invasion was examined in a Boyden chamber (C); polycarbonate filters (pore size, 8 μ m) were pre-coated with matrigel. The migration (B) and invasion (D) ability of SAS cells were quantified by counting the number of cells that invaded the underside of the porous polycarbonate membrane under microscopy and represent the average of three experiments. ***p<0.001 as compared with the untreated control.

in 4% formaldehyde in PBS for 15 min and then were permeabilized with 0.3% Triton-X 100 in PBS for 1 h with blocking of non-specific binding sites using 2% Bovine serum albumin (BSA) (30). The fixed cells were stained by primary antibodies to RhoA, ROCK1 and NF- κ B (1:100 dilution) (green fluorescence) overnight then were washed twice with PBS. All samples were the stained with secondary antibody [Fluorescein isothiocyanate (FITC)-conjugated goat antimouse IgG at 1:100 dilution], followed by DNA staining with mitotracker (Invitrogen, Carlsbad, CA, USA) (red fluorescence) as described previously (29, 30). All samples on 4-well chambers were examined and photomicrographed by using a Leica TCS SP2 Confocal Spectral Microscope (Leica Microsystems, HD, DE).

Statistical analysis. Data are presented as means \pm S.D. Differences of the variables between quercetin–treated and untreated (control) groups were analyzed by Student's *t*-test. Differences were considered significant when p<0.05.

Results

Effects of quercetin on the percentage of viable SAS cells in vitro. After SAS cells were treated with different concentrations of quercetin for 24 h, cells from each treatment were collected individually for PI staining in order to measure the percentage of viable cell. As shown in Figure 1, there were



Figure 4. Quercetin inhibited as matrix metallopeptidase-2 (MMP-2) and matrix metallopeptidase-9 (MMP-9) activities in SAS cells. Cells were incubated with 0, 10, 15, 20, 25 and 50 μ M of quercetin for 24 and 48 h. Cells were harvested and proteins separated by gelatin zymography, as described in Materials and Methods. The ratio of MMP-2 and MMP-9 activities was quantified. ***p<0.001 as compared with the untreated control.

fewer viable cells (p<0.05), as concentration of quercetin increased at 24 h (Figure 1) compared to the control group. Quercetin induced concentration-dependent responses at both examined time points.





Figure 5. Quercetin affected on the levels of proteins associated with migration and invasion in SAS cells. Cells were treated with 0, 25 and 50 µM of quercetin for 24 and 48 h and then harvested. The total proteins from each treatment were collected and the proteins levels (A: matrix metalloproteinase (MMP)-2, -7, -9 and -10 and vascular endothelial growth factor (VEGF); B: nuclear factor kappa-light-chain-enhancer of activated B cells (NF-KB) p65, inductible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) and urokinase-type plasminogen activator (uPA); C: phosphatidylinositide 3-kinases (PI3K), nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (IKB α), IKB- α/β , phosphorylated nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor kinase, alpha/ beta (p-IKK α/β); D: focal adhesion kinase (FAK), son of sevenless homolog-1 (SOS1), Ras homolog gene family, member A (RhoA), growth factor receptor-bound protein-2 (GRB2), protein kinase C (PKC), rat sarcoma viral oncogene homolog (RAS), mitogen-activated protein kinase kinase kinase-3 (MEKK3) and MEKK7; E: extracellular-signal-regulated kinase 1/2 (ERK1/2), phosphorylatedextracellular-signal-regulated kinase 1/2 (p-ERK1/2), c-Jun N-terminal kinase 1/2 (JNK1/2), p38, p-p38, Jun proto-oncogene (c-JUN) and phosphorylated-Jun proto-oncogene (p-c-JUN), were investigated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and western blotting, as described in Materials and Methods.



Figure 6. Quercetin affected Ras homolog gene family, member A (RhoA), Rho-associated, coiled-coil containing protein kinase-1 (ROCK1) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) p65 expression in SAS cells. Cells were incubated with quercetin at 25 μ M for 24 h. Cells were the stained with RhoA (A), ROCK1 (B) and NF- κ B p65 (C) FITC-labeled secondary antibodies (green fluorescence) and the proteins were detected by a confocal laser microscopy system. Scale bar 20 μ m.



Figure 7. The proposed schematic presentation of the mechanism of quercetin-inhibited migration and invasion of SAS human oral cancer cells. (matrix metalloproteinase (MMP)-2, -7, -9 and -10, nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) p65, inductible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), urokinase-type plasminogen activator (uPA), phosphatidylinositide 3-kinases (PI3K), phosphorylated nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor kinase, alpha/ beta (p-IKKa/ β), son of sevenless homolog-1 (SOS1), growth factor receptor-bound protein-2 (GRB2), mitogen-activated protein kinase kinase kinase-3 (MEKK3), MEKK7, extracellular-signal-regulated kinase 1/2 (ERK1/2), c-Jun N-terminal kinase 1/2 (JNK1/2), p38, Ras homolog gene family, member A (RhoA), protein kinase C (PKC) and rat sarcoma viral oncogene homolog (RAS).

Effects of quercetin on in vitro wound closure by SAS cells. We investigated the effects of quercetin on the migration of SAS cells by means of a wound closure assay. Figure 2 indicates that the relative wound closure was higher in control cells when compared with quercetin-treated cells. The inhibition was observed when cells were incubated with quercetin at 25 and 50 μ M for a 12 and 24 h treatment, respectively. These effects demonstrated that quercetin inhibited cell migration in a dose- and time-dependent manner (Figure 2).

Effects of quercetin on migration and invasion of SAS cells. It is well-known that multiple steps and associated factors are involved in cancer cell migration and invasion (6, 7). Thus, we further investigated whether quercetin inhibits migration and invasion of SAS cells *in vitro*. The results from the migration assay showed that quercetin had a significant inhibitory effect on cell migration at concentrations between 25-50 μ M (Figure 3A). Data in Figure 3B indicate that the inhibition was at least 42% and 44% at 24 and 48 h, when cells were treated with quercetin for 24 and 48 h, respectively.

The invasion assay indicates that quercetin had a significant inhibitory effect on invasion (the penetration of the EHS-coated filter by SAS cells) of SAS cells, cell in the upper chamber to the lower chamber in the absence of quercetin (control group) were high (Figure 3C). The percentage inhibition at 25 and 50 μ M was at least 62% and 55%, respectively (Figure 3D), when cells were incubated with quercetin for 24 and 48 h, respectively.

Effects of quercetin on MMP-2 and MMP-9 activities in SAS cells. Evidence has shown that MMP-2 and -9 play and important roles in invasion of human cancer cells (9-11). We examined whether quercetin could inhibit the secretion of MMP-2 and -9 in SAS cells by using gelatin zymography. After exposure to quercetin (0, 10, 15, 20, 25 and 50 μ M) for 24 and 48 h, cells were harvested and the results of zymography are shown in Figure 4, which indicates that quercetin inhibited MMP-9 and MMP-2 activities of SAS cells.

Effects of quercetin on levels of protein expression associated with migration and invasion in SAS cells. For investigating whether or not quercetin inhibits the migration and invasion of SAS cells via the inhibition of associated proteins, the levels of proteins from each treatment were investigated by western blotting and results are presented in Figure 5. The results in Figure 5 show that quercetin reduced the protein levels of MMP-2, -7, -9 and -10 and VEGF (Figure 5A), NF-KB p65, iNOS, COX-2 and uPA (Figure 5B), PI3K, IKB- α , IKB- α/β , p-IKK α/β (Figure 3C), FAK, SOS1, GRB2, MEKK3 and MEKK7 (Figure D), ERK1/2, p-ERK1/2, JNK1/2, p38, p-p38, c-JUN and p-c-JUN (Figure 5E), but did not affected RhoA, PKC and RAS (Figure 5D) in SAS cells. It was reported that the ERK signaling pathway up-regulates the expression of MMPs (31, 32). We, thus, tested the effects of quercetin on the ERK signaling pathway. The results indicate that quercetin inhibited the phosphorylation of ERK1/2 (Figure 5E) in SAS cancer cells at 48 h, indicating that quercetin can inhibit the ERK signaling pathway.

Quercetin affected RhoA, ROCK1 and NF-κB expression in SAS cells. Based on the results from western blotting, revealing that quercetin affected the protein levels of RhoA, and NF-κB (Figure 5) in SAS cells, confocal laser microscopy examination indicated that quercetin promoted the expression of RhoA, ROCK1 and NF-κB (Figure 6) in SAS cells.

Discussion

It is well-documented that tumor metastasis occurs through multiple steps such as vessel formation and angiogenesis, cell attachment and adhesion, invasion, migration and cell proliferation, and that it is regulated through complex mechanisms (33). The migration and invasion of cancer cells involve the expression of MMPs (8, 9). The high incidence of lymph node spread and distant metastases associated with oral cancer make for poor prognosis of this disease (34). We previously elucidated the effect of quercetin on oral cancer cell death through cell-cycle arrest and induction of apoptosis. In this study, we investigated the effects of quercetin on the migration and invasion of SAS oral cancer cells (Figure 2 and 3) *in vitro* by using a Boyden chamber assay to quantify for the migratory potential of SAS cells.

The inhibitory effect of quercetin on SAS human oral cancer cells was concentration-dependent. Furthermore, we found that quercetin inhibited the migration and invasion of SAS cells through inhibition of expression and activity of MMP-2 and -9. The inhibition of MMP expression or enzyme activity can be used as early targets for preventing cancer metastasis (9, 11, 35). MMP-2 and -9 have been shown to be involved in the invasive metastatic potential of tumor cells (36, 37).

In the present study, we found that quercetin inhibited the invasion and migration of SAS cells, which may account for its inhibitory effect on tumor metastasis. Quercetin inhibited the protein expression and activities of MMP-2 and -9 (Figure 4 and 5A), inhibited the protein expression of ERK1/2 (Figure 5E), which is involved in promoting tumor invasion and metastasis, and inhibited the protein expression of JNK (Figure 5E). Therefore, we found that quercetin alone suppressed the proliferation and migration and invasion of SAS cells *in vitro*.

In this study, our results showed that quercetin reduced the protein levels of PI3K, NF-KB, MMP-2 and MMP-9. AKT is an important downstream target of PI3K for regulating cell proliferation and is involved in cell-cycle regulation and apoptosis (38, 39), and cell invasion (37, 40). Therefore, the P13K/AKT and MAPK pathways could play significant roles as potential targets for oral cancer treatment. Herein, based on those observations, we suggest that the regulation of NF-KB, downstream of PI3K and MAPK (ERK1/2, p38 and JNK) pathways, might be involved in quercetin suppression of MMP-2 and -9 expression and activity for the inhibition of SAS cell invasion and migration. Other investigators have shown that quercetin significantly reduces the rat sarcoma viral oncogene homolog (RAS) and v-raf-1 murine leukemia viral oncogene homolog-1 (RAF1) expression, thereby reducing the cell-cycle progression in PC-3 human prostate cancer cells (41). RAS regulates several cell-cycle proteins; it inactivates the Rb protein through the activation of G₁/Cyclin-dependent kinases (CDKs) (42). However, the present study did not show that quercetin inhibited RAS expression in SAS cells. It was reported that quercetin inhibited the migration and invasion of PC-3 through downregulating uPA, uPAR, epidermal growth factor (EGF) and EGF-R mRNA expressions (41). uPA is a serine protease that is involved in cancer progression, especially invasion and metastasis (41). We found that quercetin inhibited the migration and invasion of SAS cells through the down-regulation of NF-KB, causing the inhibition of the protein expression and activity of MMP-2 and -9. Apparently, quercetin-inhibited migration and invasion of cancer cells may have cell specificity. Further investigations are needed to determine this.

In conclusion, this study has shown the quercetin, a plant compound, caused the inhibition of invasion and migration of SAS human oral cancer cells. Quercetin inhibited the activity of MMP-2 and -9 in a concentration-dependent manner. The possible signal pathways for quercetin inhibition of migration and invasion in SAS cells may be *via* inhibition of MMP-2 and MMP-9 *via* down-regulation of PKC, blocking of MAPK and PI3K signaling pathways and both COX-2 and NF-KB (Figure 7).

Acknowledgements

This study was supported by a research grant (DOH101-TD-C-111-005) from Taiwan Department of Health, China Medical University Hospital Cancer Research Center of Excellence.

References

- 1 Sanjiv K, Su TL, Suman S, Kakadiya R, Lai TC, Wang HY, Hsiao M and Lee TC: The novel DNA alkylating agent BO-1090 suppresses the growth of human oral cavity cancer in xenografted and orthotopic mouse models. Int J Cancer 130: 1440-1450, 2012.
- 2 Al-Swiahb JN, Chen CH, Chuang HC, Fang FM, Tasi HT and Chien CY: Clinical, pathological and molecular determinants in squamous cell carcinoma of the oral cavity. Future Oncol 6: 837-850, 2010.
- 3 Liu SY, Lu CL, Chiou CT, Yen CY, Liaw GA, Chen YC, Liu YC and Chiang WF: Surgical outcomes and prognostic factors of oral cancer associated with betel quid chewing and tobacco smoking in Taiwan. Oral Oncol 46: 276-282, 2010.
- Yu FS, Yang JS, Yu CS, Lu CC, Chiang JH, Lin CW and Chung JG: Safrole induces apoptosis in human oral cancer HSC-3 cells. J Dent Res *90*: 168-174, 2011.
- 5 Choi Y, Kim SY, Kim SH, Yang J, Park K and Byun Y: Inhibition of tumor growth by biodegradable microspheres containing alltrans-retinoic acid in a human head-and-neck cancer xenograft. Int J Cancer 107: 145-148, 2003.
- 6 Kilian M, Gregor JI, Heukamp I, Hanel M, Ahlgrimm M, Schimke I, Kristiansen G, Ommer A, Walz MK, Jacobi CA and Wenger FA: Matrix metalloproteinase inhibitor RO 28-2653 decreases liver metastasis by reduction of MMP-2 and MMP-9 concentration in BOP-induced ductal pancreatic cancer in Syrian Hamsters: Inhibition of matrix metalloproteinases in pancreatic cancer. Prostaglandins Leukot Essent Fatty Acids 75: 429-434, 2006.
- 7 Mizutani K, Kofuji K and Shirouzu K: The significance of MMP-1 and MMP-2 in peritoneal disseminated metastasis of gastric cancer. Surg Today 30: 614-621, 2000.
- 8 Gullu IH, Kurdoglu M and Akalin I: The relation of gelatinase (MMP-2 and -9) expression with distant site metastasis and tumour aggressiveness in colorectal cancer. Br J Cancer 82: 249, 2000.
- 9 Guruvayoorappan C and Kuttan G: Amentoflavone inhibits experimental tumor metastasis through a regulatory mechanism

involving MMP-2, MMP-9, prolyl hydroxylase, lysyl oxidase, VEGF, ERK-1, ERK-2, STAT-1, NM23 and cytokines in lung tissues of C57BL/6 mice. Immunopharmacol Immunotoxicol *30*: 711-727, 2008.

- 10 Okada N, Ishida H, Murata N, Hashimoto D, Seyama Y and Kubota S: Matrix metalloproteinase-2 and -9 in bile as a marker of liver metastasis in colorectal cancer. Biochem Biophys Res Commun 288: 212-216, 2001.
- 11 Waas ET, Wobbes T, Lomme RM, DeGroot J, Ruers T and Hendriks T: Matrix metalloproteinase-2 and -9 activity in patients with colorectal cancer liver metastasis. Br J Surg *90*: 1556-1564, 2003.
- 12 Lai KC, Huang AC, Hsu SC, Kuo CL, Yang JS, Wu SH, and Chung JG: Benzyl isothiocyanate (BITC) inhibits migration and invasion of human colon cancer HT29 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen (uPA) through PKC and MAPK signaling pathway. J Agric Food Chem *58*: 2935-2942, 2010.
- 13 Festuccia C, Giunciuglio D, Guerra F, Villanova I, Angelucci A, Manduca P, Teti A, Albini A and Bologna M: Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion. Oncol Res 11: 17-31, 1999.
- 14 Duffy MJ: The urokinase plasminogen activator system: Role in malignancy. Curr Pharm Des *10*: 39-49, 2004.
- 15 van Erk MJ, Roepman P, van der Lende TR, Stierum RH, Aarts JMMJG, van Bladeren PJ and van Ommen B: Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells *in vitro*. Eur J Nutr 44: 143-156, 2005.
- 16 Lee TJ, Kim OH, Kim YH, Lim JH, Kim S, Park JW and Kwon TK: Quercetin arrests G₂/M phase and induces caspase-dependent cell death in U937 cells. Cancer Lett 240: 234-242, 2006.
- 17 Singhal RL, Yeh YA, Praja N, Olah E, Sledge GW Jr. and Weber G: Quercetin down-regulates signal transduction in human breast carcinoma cells. Biochem Biophys Res Commun 208: 425-431, 1995.
- 18 Nguyen TT, Tran E, Nguyen TH, Do PT, Huynh TH and Huynh H: The role of activated MEK-ERK pathway in quercetininduced growth inhibition and apoptosis in A549 lung cancer cells. Carcinogenesis 25: 647-659, 2004.
- 19 Chi YS, Jong HG, Son KH, Chang HW, Kang SS and Kim HP: Effects of naturally occurring prenylated flavonoids on enzymes metabolizing arachidonic acid: Cyclooxygenases and lipoxygenases. Biochem Pharmacol 62: 1185-1191, 2001.
- 20 Ong CS, Tran E, Nguyen TT, Ong CK, Lee SK, Lee JJ, Ng CP, Leong C and Huynh H: Quercetin-induced growth inhibition and cell death in nasopharyngeal carcinoma cells are associated with increase in Bad and hypophosphorylated retinoblastoma expressions. Oncol Rep 11: 727-733, 2004.
- 21 Kim MK, Jung HS, Yoon CS, Ko JH, Chun HJ, Kim TK, Kwon MJ, Lee SH, Koh KS, Rhee BD and Park JH: EGCG and quercetin protected INS-1 cells in oxidative stress *via* different mechanisms. Front Biosci 2: 810-817, 2010.
- 22 Sun ZJ, Chen G, Hu X, Zhang W, Liu Y, Zhu LX, Zhou Q, and Zhao YF: Activation of PI3K/AKT/IKK-α/NF-κB signaling pathway is required for the apoptosis-evasion in human salivary adenoid cystic carcinoma: Its inhibition by quercetin. Apoptosis 15: 850-863, 2010.

- 23 Lu KW, Chen JC, Lai TY, Yang JS, Weng SW, Ma YS, Lu PJ, Weng JR, Chueh FS, Wood WG and Chung JG: Gypenosides inhibit migration and invasion of human oral cancer SAS cells through the inhibition of matrix metalloproteinase-2 -9 and urokinase-plasminogen by ERK1/2 and NF-κB signaling pathways. Hum Exp Toxicol 30: 406-415, 2011.
- 24 Lu KW, Chen JC, Lai TY, Yang JS, Weng SW, Ma YS, Lin HY, Wu RS, Wu KC, Wood WG and Chung JG: Gypenosides suppress growth of human oral cancer SAS cells *in vitro* and in a murine xenograft model: the role of apoptosis mediated by caspase-dependent and caspase-independent pathways. Integr Cancer Ther *11*: 129-140, 2012.
- 25 Chen YY, Chiang SY, Lin JG, Ma YS, Liao CL, Weng SW, Lai TY and Chung JG: Emodin, aloe-emodin and rhein inhibit migration and invasion in human tongue cancer SCC-4 cells through the inhibition of gene expression of matrix metalloproteinase-9. Int J Oncol 36: 1113-1120, 2010.
- 26 Liu KC, Huang AC, Wu PP, Lin HY, Chueh FS, Yang JS, Lu CC, Chiang JH, Meng M and Chung JG: Gallic acid suppresses the migration and invasion of PC-3 human prostate cancer cells *via* inhibition of matrix metalloproteinase-2 and -9 signaling pathways. Oncol Rep 26: 177-184, 2011.
- 27 Lin HJ, Su CC, Lu HF, Yang JS, Hsu SC, Ip SW, Wu JJ, Li YC, Ho CC, Wu CC and Chung JG: Curcumin blocks migration and invasion of mouse-rat hybrid retina ganglion cells (N18) through the inhibition of MMP-2, -9, FAK, RhoA and ROCK1 gene expression. Oncol Rep 23: 665-670, 2010.
- 28 Lu CC, Yang JS, Huang AC, Hsia TC, Chou ST, Kuo CL, Lu HF, Lee TH, Wood WG and Chung JG: Chrysophanol induces necrosis through the production of ROS and alteration of ATP levels in J5 human liver cancer cells. Mol Nutr Food Res 54: 967-976, 2010.
- 29 Chiang JH, Yang JS, Ma CY, Yang MD, Huang HY, Hsia TC, Kuo HM, Wu PP, Lee TH and Chung JG: Danthron, an anthraquinone derivative, Induces DNA damage and caspase cascade-mediated apoptosis in SNU-1 human gastric cancer cells through mitochondrial permeability transition pores and BAXtriggered pathways. Chem Res Toxicol 24: 20-29, 2011.
- 30 Kuo JH, Chu YL, Yang JS, Lin JP, Lai KC, Kuo HM, Hsia TC and Chung JG: Cantharidin induces apoptosis in human bladder cancer TSGH 8301 cells through mitochondria-dependent signal pathways. Int J Oncol 37: 1243-1250, 2010.
- 31 Jinnin M, Ihn H, Mimura Y, Asano Y, Yamane K and Tamaki K: Matrix metalloproteinase-1 up-regulation by hepatocyte growth factor in human dermal fibroblasts via ERK signaling pathway involves ETS1 and FLI1. Nucleic Acids Res 33: 3540-3549, 2005.

- 32 Hu YB, Zong YR, Feng DY, Jin ZY, Jiang HY and Peng JW: p38/ERK signal pathways regulating the expression of type I collagen and activity of MMP-2 in TGF-β-stimulated HLF-02 cells. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 24: 77-80, 2006 (in Chinese)
- 33 Fidler IJ: The organ microenvironment and cancer metastasis. Differentiation 70: 498-505, 2002.
- 34 Nair S, Phillips AO, Norton N, Spurlock G, Williams HJ, Craig KJ, Williams JD, Williams NM, Bowen T: Further evidence for the association of MMP9 with nephropathy in type 2 diabetes and application of DNA pooling technology to candidate gene screening. J Nephrol 21: 400-405, 2008.
- 35 Coussens LM and Werb Z: Matrix metalloproteinases and the development of cancer. Chem Biol *3*: 895-904, 1996.
- 36 Zhang L, Shi J, Feng J, Klocker H, Lee C and Zhang J: Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer Prostatic Dis 7: 327-332, 2004.
- 37 Eccles SA: Parallels in invasion and angiogenesis provide pivotal points for therapeutic intervention. Int J Dev Biol 48: 583-598, 2004.
- 38 Datta SR, Brunet A and Greenberg ME: Cellular survival: A play in three AKTs. Genes Dev 13: 2905-2927, 1999.
- 39 Liang J and Slingerland JM: Multiple roles of the PI3K/PKB (AKT) pathway in cell cycle progression. Cell Cycle 2: 339-345, 2003.
- 40 Hollborn M, Stathopoulos C, Steffen A, Wiedemann P, Kohen L and Bringmann A: Positive feedback regulation between MMP-9 and VEGF in human RPE cells. Invest Ophthalmol Vis Sci 48: 4360-4367, 2007.
- 41 Senthilkumar K, Arunkumar R, Elumalai P, Sharmila G, Gunadharini DN, Banudevi S, Krishnamoorthy G, Benson CS, Arunakaran J: Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3). Cell Biochem Funct *29*: 87-95, 2011.
- 42 Nevins JR: The Rb/E2F pathway and cancer. Hum Mol Genet *10*: 699-703, 2001.

Received February 20, 2013 Revised April 1, 2013 Accepted April 2, 2013